Find information on thousands of medical conditions and prescription drugs.

Trovafloxacin

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
Oxytetracycline
Phentermine
Tacrine
Tacrolimus
Tagamet
Talbutal
Talohexal
Talwin
Tambocor
Tamiflu
Tamoxifen
Tamsulosin
Tao
Tarka
Taurine
Taxol
Taxotere
Tazarotene
Tazobactam
Tazorac
Tegretol
Teicoplanin
Telmisartan
Temazepam
Temocillin
Temodar
Temodar
Temozolomide
Tenex
Teniposide
Tenoretic
Tenormin
Tenuate
Terazosin
Terbinafine
Terbutaline
Terconazole
Terfenadine
Teriparatide
Terlipressin
Tessalon
Testosterone
Tetrabenazine
Tetracaine
Tetracycline
Tetramethrin
Thalidomide
Theo-24
Theobid
Theochron
Theoclear
Theolair
Theophyl
Theophyl
Theostat 80
Theovent
Thiamine
Thiomersal
Thiopental sodium
Thioridazine
Thorazine
Thyroglobulin
Tiagabine
Tianeptine
Tiazac
Ticarcillin
Ticlopidine
Tikosyn
Tiletamine
Timolol
Timoptic
Tinidazole
Tioconazole
Tirapazamine
Tizanidine
TobraDex
Tobramycin
Tofranil
Tolazamide
Tolazoline
Tolbutamide
Tolcapone
Tolnaftate
Tolterodine
Tomoxetine
Topamax
Topicort
Topiramate
Tora
Toradol
Toremifene
Tracleer
Tramadol
Trandate
Tranexamic acid
Tranxene
Tranylcypromine
Trastuzumab
Trazodone
Trenbolone
Trental
Trest
Tretinoin
Triacetin
Triad
Triamcinolone
Triamcinolone hexacetonide
Triamterene
Triazolam
Triclabendazole
Triclosan
Tricor
Trifluoperazine
Trilafon
Trileptal
Trimetazidine
Trimethoprim
Trimipramine
Trimox
Triprolidine
Triptorelin
Tritec
Trizivir
Troglitazone
Tromantadine
Trovafloxacin
Tubocurarine chloride
Tussionex
Tylenol
Tyrosine
U
V
W
X
Y
Z

Read more at Wikipedia.org


[List your site here Free!]


Comparative efficacy of oral and sequential intravenous/oral moxifloxacin in the treatment of community acquired pneumonia in the very elderly
From CHEST, 10/1/05 by Antonio Anzueto

PURPOSE: To evaluate the efficacy and safety of sequential IV/PO and PO moxifloxacin (MXF) versus that of comparator (COMP) antibiotics in very elderly ([greater than or equal to] 75 years old) patients with CAP.

METHODS: Data were pooled from all global, randomized, controlled trials of IV/PO (5 trials) and PO (5 trials) of MXF in the treatment of CAP. The pooled data were used to determine the clinical success rates and adverse event rates in the very elderly for both MXF and COMP-treated patients. The comparators were clarithromycin and amoxicillin in the PO studies and trovafloxacin, levofloxacin, ceftriaxone [+ or -] azithromycin and amoxicillin/clavulanate [+ or -] clarithromycin in the sequential IV/PO studies.

RESULTS: Of the 908 very elderly patients identified in the pooled analysis, 215 (114 MXF, 101 COMP) received PO and 693 (349 MXF, 344 COMP) received sequential IV/PO therapy. Of these, 158 PO-treated (84 MXF, 74 COMP) and 497 IV/PO-treated (248 MXF, 249 COMP) patients were valid for the primary efficacy analysis. Clinical success rates in IV/PO studies were 90% (222/248) for MXF vs. 83% (206/249) for COMP (95% CI 0.3%, 12%). For PO studies clinical success rates were 95% (80/84) for MXF vs. 86% (64/74) for COMP (95% CI 0.7%, 18.6%). Adverse and serious adverse event rates were similar in MXF- and COMP-treated patients.

CONCLUSION: Both IV and PO moxifloxacin were highly efficacious and safe in treating community acquired pneumonia in the very elderly and overall cure rates were significantly better in moxifloxacin treated-patients than those achieved with the comparator regimens.

CLINICAL IMPLICATIONS: Moxifloxacin appears to have excellent efficacy when used as empiric monotherapy for the treatment of CAP in very elderly patients.

DISCLOSURE: Antonio Anzueto, Employee Dan Haverstock, Frank Kruesmann, Shurjeel Choudhri; Consultant fee, speaker bureau, advisory committee, etc.

Antonio Anzueto MD * Daniel Haverstock MS Frank Kruesmann PhD Shurjeel Choudhri MD Univ. of Texas Health Sci. Ctr., San Antonio, TX

COPYRIGHT 2005 American College of Chest Physicians
COPYRIGHT 2005 Gale Group

Return to Trovafloxacin
Home Contact Resources Exchange Links ebay